Congressional Report Clarifies Limits of Federal Marijuana Rescheduling for State-Legal Markets

A new report from the Congressional Research Service (CRS) has clarified the complex implications of the Trump administration’s decision to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act. According to the CRS, while the move marks a significant shift in federal cannabis policy, it does not immediately resolve the ongoing conflict between state-legal marijuana businesses and federal law. The report highlights that state-licensed cannabis companies remain out of full compliance with federal regulations despite the rescheduling

The CRS report further explains that the rescheduling appears to grant medical marijuana users broader protections, noting it "appears to authorize end users to possess marijuana for medical use without a [Controlled Substances Act]-compliant prescription." However, the document makes clear that this does not extend to the commercial activities of producers or retailers operating under state law. The distinction is crucial for the industry, which has long sought clarity on the legal risks of operating in a federally prohibited environment

This federal update comes as several states continue to grapple with their own cannabis policies. In Idaho, a medical cannabis campaign has submitted over 150,000 signatures—more than twice the required number—to qualify a legalization initiative for the November ballot. Meanwhile, efforts to roll back legalization in Arizona have stalled after campaign leaders reconsidered the perceived risks to youth, with the initiative’s head stating, "I have adjusted my viewpoints on the threat to kids."

On the regulatory front, the market is also facing new uncertainties. Target is expanding its sales of hemp-derived THC beverages into three major U.S. states, even as federal law is poised to recriminalize such products later this year. Louisiana legislators are considering harsher penalties for marijuana use near schools, and various states, including Maryland and California, are issuing new regulatory guidance in response to the rescheduling and evolving federal stance

Industry stakeholders and lawmakers are weighing in on these developments. Sen. Rand Paul (R-KY) voiced strong opposition to a federal hemp ban, arguing, "A federal hemp ban would devastate American farmers and small businesses while pushing products into unregulated markets." Meanwhile, Nebraska Senate candidate Dan Osborn described the rescheduling as "a win for Nebraska farmers and a win for patients and caregivers who can finally access the medicine they need."

From the OG Lab newsroom perspective, the CRS report underscores that federal rescheduling is only a partial victory for the cannabis sector. While patients may benefit from reduced legal risks, businesses still face considerable uncertainty. This development is worth watching as it could shape future federal and state policy debates, especially as states continue to innovate and federal authorities refine their approach to cannabis regulation